
Remedium Lifecare (REMLIFE) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Jun 2025Income Metrics
Revenue
1.1B
Gross Profit
55.4M
4.88%
Operating Income
18.7M
1.65%
Net Income
46.5M
4.10%
EPS (Diluted)
₹0.05
Balance Sheet Metrics
Total Assets
17.2B
Total Liabilities
16.8B
Shareholders Equity
438.9M
Debt to Equity
38.20
Cash Flow Metrics
Revenue & Profitability Trend
Remedium Lifecare Income Statement From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Revenue | 4.1B | 40.4B | 5.1B | 5.0B | 900.3M |
Cost of Goods Sold | 4.0B | 40.0B | 4.9B | 5.0B | 879.2M |
Gross Profit | 71.2M | 403.3M | 159.8M | 63.1M | 21.1M |
Gross Margin % | 1.8% | 1.0% | 3.1% | 1.3% | 2.3% |
Operating Expenses | |||||
Research & Development | - | - | - | - | - |
Selling, General & Administrative | - | 12.3M | 36.8M | 12.7M | 5.3M |
Other Operating Expenses | 74.5M | 29.6M | 19.7M | 23.4M | 3.8M |
Total Operating Expenses | 74.5M | 41.9M | 56.5M | 36.1M | 9.2M |
Operating Income | -11.3M | 341.5M | 85.7M | 17.4M | 6.6M |
Operating Margin % | -0.3% | 0.8% | 1.7% | 0.3% | 0.7% |
Non-Operating Items | |||||
Interest Income | - | 0 | 755.0K | 0 | 0 |
Interest Expense | 52.9M | 40.2M | 717.0K | 1.8M | 113.0K |
Other Non-Operating Income | - | - | - | - | - |
Pre-tax Income | 43.8M | 504.5M | 74.0M | 15.3M | 6.5M |
Income Tax | 22.5M | 177.2M | 19.7M | 4.5M | 1.7M |
Effective Tax Rate % | 51.4% | 35.1% | 26.6% | 29.3% | 26.4% |
Net Income | 21.3M | 327.3M | 54.3M | 10.8M | 4.8M |
Net Margin % | 0.5% | 0.8% | 1.1% | 0.2% | 0.5% |
Key Metrics | |||||
EBITDA | 97.1M | 545.1M | 91.6M | 17.7M | 7.2M |
EPS (Basic) | ₹0.03 | ₹0.81 | ₹3.77 | ₹0.03 | ₹0.01 |
EPS (Diluted) | ₹0.03 | ₹0.81 | ₹3.77 | ₹0.03 | ₹0.01 |
Basic Shares Outstanding | 610147381 | 403200000 | 14400000 | 403200000 | 403200000 |
Diluted Shares Outstanding | 610147381 | 403200000 | 14400000 | 403200000 | 403200000 |
Income Statement Trend
Remedium Lifecare Balance Sheet From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 2.8M | 2.7M | 2.4M | 7.0M | 6.6M |
Short-term Investments | 11.5M | 12.8M | 216.1M | 7.4M | 1.5M |
Accounts Receivable | 7.7B | 9.2B | 1.7B | 640.0M | 236.8M |
Inventory | 2.7B | 1.3B | 73.2M | 838.7M | 31.1M |
Other Current Assets | 25.0M | 1.0K | -1.0K | -2.0K | -1.0K |
Total Current Assets | 17.2B | 19.5B | 11.5B | 2.2B | 383.2M |
Non-Current Assets | |||||
Property, Plant & Equipment | 83.0K | 470.0K | 781.0K | 854.0K | 730.0K |
Goodwill | 0 | 0 | 0 | 1.0M | 1.4M |
Intangible Assets | - | - | - | 1.0M | 1.4M |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | - | 8.0K | - | -1.0K | -1.0K |
Total Non-Current Assets | 441.0K | 737.0K | 855.0K | 1.9M | 2.1M |
Total Assets | 17.2B | 19.5B | 11.5B | 2.2B | 385.3M |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 5.0B | 7.1B | 842.2M | 1.2B | 237.7M |
Short-term Debt | 11.4B | 577.0M | 0 | 0 | 0 |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | 317.2M | 1.0M | 2.0M | 1.3M | 75.0K |
Total Current Liabilities | 16.8B | 19.0B | 11.4B | 2.2B | 241.7M |
Non-Current Liabilities | |||||
Long-term Debt | 0 | 0 | 0 | 0 | 105.0M |
Deferred Tax Liabilities | 0 | 0 | 0 | 1.0K | 34.0K |
Other Non-Current Liabilities | -1.0K | - | - | - | - |
Total Non-Current Liabilities | -1.0K | 0 | 0 | 1.0K | 105.0M |
Total Liabilities | 16.8B | 19.0B | 11.4B | 2.2B | 346.8M |
Equity | |||||
Common Stock | 403.2M | 100.8M | 36.0M | 36.0M | 36.0M |
Retained Earnings | - | 328.8M | 65.5M | 11.2M | 417.0K |
Treasury Stock | - | - | - | - | - |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 438.9M | 429.6M | 103.6M | 49.4M | 38.6M |
Key Metrics | |||||
Total Debt | 11.4B | 577.0M | 0 | 0 | 105.0M |
Working Capital | 438.5M | 428.8M | 102.8M | 47.5M | 141.5M |
Balance Sheet Composition
Remedium Lifecare Cash Flow Statement From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | 43.8M | 504.5M | 74.0M | 15.3M | 6.5M |
Depreciation & Amortization | - | - | - | - | - |
Stock-Based Compensation | - | - | - | - | - |
Working Capital Changes | -16.5B | -7.5B | 532.0M | -912.2M | -342.7M |
Operating Cash Flow | -16.4B | -7.0B | 606.3M | -895.8M | -336.2M |
Investing Activities | |||||
Capital Expenditures | - | - | 0 | 0 | 0 |
Acquisitions | 0 | - | - | - | - |
Investment Purchases | - | - | - | - | - |
Investment Sales | - | - | - | - | - |
Investing Cash Flow | 1.3M | - | 0 | 0 | 0 |
Financing Activities | |||||
Share Repurchases | - | - | - | - | - |
Dividends Paid | - | - | - | - | - |
Debt Issuance | 0 | 0 | 0 | 0 | 101.4M |
Debt Repayment | - | 0 | 0 | -105.0M | - |
Financing Cash Flow | 11.4B | 577.0M | 0 | -105.0M | 101.4M |
Free Cash Flow | -11.4B | -741.6M | 204.6M | 112.3M | -102.5M |
Net Change in Cash | -5.0B | -6.4B | 606.3M | -1.0B | -234.8M |
Cash Flow Trend
Remedium Lifecare Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
25.17
Price to Book
1.41
Price to Sales
0.30
PEG Ratio
0.32
Profitability Ratios
Profit Margin
1.17%
Operating Margin
1.65%
Return on Equity
4.85%
Return on Assets
0.12%
Financial Health
Current Ratio
1.03
Debt to Equity
2,600.51
Beta
1.20
Per Share Data
EPS (TTM)
₹0.06
Book Value per Share
₹1.07
Revenue per Share
₹7.93
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
remlife | 1.3B | 25.17 | 1.41 | 4.85% | 1.17% | 2,600.51 |
Sun Pharmaceutical | 3.9T | 37.28 | 5.37 | 15.08% | 19.29% | 3.26 |
Divi's Laboratories | 1.6T | 69.80 | 10.74 | 14.64% | 23.89% | 0.03 |
Innova Captab | 49.4B | 37.87 | 5.12 | 13.37% | 9.98% | 35.24 |
Sequent Scientific | 46.9B | 157.76 | 6.44 | 2.84% | 1.85% | 62.47 |
Sun Pharma Advanced | 46.7B | -13.68 | -21.57 | 157.88% | -53.22% | -1.24 |
Financial data is updated regularly. All figures are in the company's reporting currency.